The most common somatic genomic alterations in prostate cancer include chromosome 8p loss (resulting in the loss of NKX3.1), 10q loss (resulting in the loss of PTEN), 17q loss (resulting in the loss of TP53), 8q gain (resulting in Myc overexpression), androgen receptor alterations, SPOP mutations, and TMPRSS2-ETS gene fusions such as TMPRSS2-ERG. This evidence concerns the gene TMPRSS2 and prostate cancer.